Breakthrough for Psychedelic Medicine - Alli Feduccia, Ph.D.

MDMA-assisted psychotherapy stands as a promising experimental treatment for post-traumatic stress disorder (PTSD). Clinical research indicates that this therapeutic approach offers significant benefits for individuals suffering from PTSD, a condition that affects up to 7 percent of the general population and a much higher percentage of military veterans. Following successful phase 2 trials where 56 percent of participants no longer met the criteria for PTSD two months post-treatment, the FDA granted this therapeutic model breakthrough therapy designation in 2017. Data from long-term follow-up at 12 months showed that 68 percent of participants experienced sustained remission after only 2-3 treatment sessions, highlighting the potential for MDMA-assisted therapy to outperform traditional antidepressants by mitigating the side effects associated with daily medication use.